Anti-vascular endothelial growth factor for proliferative diabetic retinopathy

Martinez‐Zapata, Maria José; Salvador, Ignacio Cabeza del; Martí‐Carvajal, Arturo J; Pijoán, José Ignacio; Cordero, José Antonio; Ponomarev, Dmitry; Kernohan, Ashleigh; Solà, Iván; Virgili, Gianni

doi:10.1002/14651858.cd008721.pub3

Cited by 7 publications

(1 citation statement)

References 174 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further studies confirmed that anti-VEGF therapy is non-inferior to PRP for the treatment of PDR [ 57 ]. Recent studies have shown benefit from intravitreal anti-VEGF alone in the treatment of PDR [ 58 , 59 , 60 ], although visual recovery is slower [ 61 ], and patients who are lost to follow-up after anti-VEGF alone are at risk of worse visual outcomes than if they had received laser treatment [ 62 ]. The combination of anti-VEGF and PRP is widely used clinically, but the benefit over PRP alone is modest [ 60 ].…”

Section: Diabetic Retinopathymentioning

confidence: 99%

Oxidative Stress and Its Regulation in Diabetic Retinopathy

Haydinger,

Oliver,

Ashander

et al. 2023

Antioxidants

View full text Add to dashboard Cite

Diabetic retinopathy is the retinal disease associated with hyperglycemia in patients who suffer from type 1 or type 2 diabetes. It includes maculopathy, involving the central retina and characterized by ischemia and/or edema, and peripheral retinopathy that progresses to a proliferative stage with neovascularization. Approximately 10% of the global population is estimated to suffer from diabetes, and around one in 5 of these individuals have diabetic retinopathy. One of the major effects of hyperglycemia is oxidative stress, the pathological state in which elevated production of reactive oxygen species damages tissues, cells, and macromolecules. The retina is relatively prone to oxidative stress due to its high metabolic activity. This review provides a summary of the role of oxidative stress in diabetic retinopathy, including a description of the retinal cell players and the molecular mechanisms. It discusses pathological processes, including the formation and effects of advanced glycation end-products, the impact of metabolic memory, and involvements of non-coding RNA. The opportunities for the therapeutic blockade of oxidative stress in diabetic retinopathy are also considered.

show abstract

Section: Diabetic Retinopathymentioning

confidence: 99%

Oxidative Stress and Its Regulation in Diabetic Retinopathy

Haydinger,

Oliver,

Ashander

et al. 2023

Antioxidants

View full text Add to dashboard Cite

show abstract

How does anti-vascular endothelial growth factor (anti-VEGF) with or without panretinal photocoagulation (PRP) compare with PRP alone for adults with proliferative diabetic retinopathy?

Anderson

2023

Cochrane Clinical Answers

View full text Add to dashboard Cite

Advances in Extracellular-Vesicles-Based Diagnostic and Therapeutic Approaches for Ocular Diseases

Su,

Chen,

et al. 2024

ACS Nano

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are nanoscale membrane vesicles of various sizes that can be secreted by most cells. EVs contain a diverse array of cargo, including RNAs, lipids, proteins, and other molecules with functions of intercellular communication, immune modulation, and regulation of physiological and pathological processes. The biofluids in the eye, including tears, aqueous humor, and vitreous humor, are important sources for EV-based diagnosis of ocular disease. Because the molecular cargos may reflect the biology of their parental cells, EVs in these biofluids, as well as in the blood, have been recognized as promising candidates as biomarkers for early diagnosis of ocular disease. Moreover, EVs have also been used as therapeutics and targeted drug delivery nanocarriers in many ocular disorders because of their low immunogenicity and superior biocompatibility in nature. In this review, we provide an overview of the recent advances in the field of EV-based studies on the diagnosis and therapeutics of ocular disease. We summarized the origins of EVs applied in ocular disease, assessed different methods for EV isolation from ocular biofluid samples, highlighted bioengineering strategies of EVs as drug delivery systems, introduced the latest applications in the diagnosis and treatment of ocular disease, and presented their potential in the current clinical trials. Finally, we briefly discussed the challenges of EV-based studies in ocular disease and some issues of concern for better focusing on clinical translational studies of EVs in the future.

show abstract

Anti-vascular endothelial growth factor for proliferative diabetic retinopathy

Abstract: Anti-vascular endothelial growth factor for proliferative diabetic retinopathy (Review)

Cited by 7 publications

References 174 publications

Oxidative Stress and Its Regulation in Diabetic Retinopathy

Oxidative Stress and Its Regulation in Diabetic Retinopathy

How does anti-vascular endothelial growth factor (anti-VEGF) with or without panretinal photocoagulation (PRP) compare with PRP alone for adults with proliferative diabetic retinopathy?

Advances in Extracellular-Vesicles-Based Diagnostic and Therapeutic Approaches for Ocular Diseases

Contact Info

Product

Resources

About